Hologic, Inc. (HOLX) Gross Margin: 52.82%
Is Hologic, Inc.’s gross margin high or low?
Hologic, Inc.'s gross margin of 52.82% is 11% below its 5-year average of 59.28%, near the low end of its 5-year range (51.40%–67.39%).
As of Thursday, June 11, 2026. 9.15% below its 12-month average of 58.14%.
HOLX Gross Margin Chart
HOLX Average Gross Margin Chart
HOLX Current vs Average Gross Margin Chart
HOLX Gross Margin Metrics
GROSS MARGIN
52.82%
GROSS MARGIN AVG TTM
58.14%
GROSS MARGIN AVG 3Y
57.33%
GROSS MARGIN AVG 5Y
59.28%
GROSS MARGIN AVG 10Y
55.31%
GROSS MARGIN AVG 15Y
53.08%
GROSS MARGIN AVG 20Y
51.57%
CURRENT VS TTM AVG
-9.15%
CURRENT VS 3Y AVG
-7.87%
CURRENT VS 5Y AVG
-10.90%
CURRENT VS 10Y AVG
-4.50%
CURRENT VS 15Y AVG
-0.50%
CURRENT VS 20Y AVG
+2.43%
HOLX Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 52.82% | 58.14% | 57.33% | 59.28% |
| Moderna, Inc. (MRNA) | $18.71B | -13.89% | 54.80% | 53.09% | 65.45% |
| Align Technology, Inc. (ALGN) | $12.27B | 67.68% | 69.16% | 69.73% | 70.75% |
| BioNTech SE (BNTX) | $22.39B | 73.26% | 78.98% | 81.24% | 82.89% |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 57.79% | 57.84% | 57.54% | 57.23% |
| Waters Corporation (WAT) | $23.21B | 55.02% | 58.60% | 58.69% | 58.45% |
| Baxter International Inc. (BAX) | $10.58B | 30.11% | 33.76% | 35.72% | 36.84% |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | 31.86% | 31.70% | 34.15% | 35.17% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 51.87% | 52.87% | 53.77% | 54.60% |
| Veeva Systems Inc. (VEEV) | $26.31B | 74.95% | 75.03% | 73.28% | 73.00% |
Gross Margin Analysis
Gross Margin
52.8%
(Revenue - COGS) / Revenue
Hologic, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. Gross Margin FAQ
- What is the gross margin for Hologic, Inc. (HOLX)?
- The gross margin for HOLX stock is 52.82%.
- Is Hologic, Inc.'s gross margin high or low?
- Hologic, Inc.'s gross margin of 52.82% is 11% below its 5-year average of 59.28%, near the low end of its 5-year range (51.40%–67.39%).
- What is the TTM average gross margin for Hologic, Inc. (HOLX)?
- The TTM average gross margin for HOLX stock is 58.14%.
- What is the 3Y average gross margin for Hologic, Inc. (HOLX)?
- The 3Y average gross margin for HOLX stock is 57.33%.
- What is the 5Y average gross margin for Hologic, Inc. (HOLX)?
- The 5Y average gross margin for HOLX stock is 59.28%.
- What is the 10Y average gross margin for Hologic, Inc. (HOLX)?
- The 10Y average gross margin for HOLX stock is 55.31%.
- What is the 15Y average gross margin for Hologic, Inc. (HOLX)?
- The 15Y average gross margin for HOLX stock is 53.08%.
- What is the 20Y average gross margin for Hologic, Inc. (HOLX)?
- The 20Y average gross margin for HOLX stock is 51.57%.
Hologic, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-09-27 | 61.00% |
| 2024-09-30 | 55.28% |
| 2023-09-30 | 51.40% |
| 2022-09-30 | 61.64% |
| 2021-09-30 | 67.39% |
| 2020-09-30 | 58.98% |
| 2019-09-30 | 38.85% |
| 2018-09-30 | 52.73% |
| 2017-09-30 | 52.99% |
| 2016-09-30 | 55.19% |
| 2015-09-30 | 52.96% |
| 2014-09-30 | 49.22% |
| 2013-09-30 | 46.60% |
| 2012-09-30 | 49.66% |
| 2011-09-30 | 51.59% |
| 2010-09-30 | 43.86% |
| 2009-09-30 | 52.38% |
| 2008-09-30 | 53.30% |
| 2007-09-30 | 46.80% |
| 2006-09-30 | 41.83% |
| 2005-09-30 | 39.29% |
| 2004-09-30 | 37.33% |
| 2003-09-30 | 36.06% |
| 2002-09-30 | 37.76% |
| 2001-09-30 | 34.91% |
| 2000-09-30 | 36.87% |
| 1999-09-30 | 44.35% |
| 1998-09-30 | 53.29% |
| 1997-09-30 | 56.70% |
| 1996-09-30 | 54.20% |
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini